Dose-volume comparison of proton radiotherapy and stereotactic body radiotherapy for non-small-cell lung cancer.

[1]  Tommy Knöös,et al.  Clinical implications of the implementation of advanced treatment planning algorithms for thoracic treatments. , 2008, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[2]  H. Satoh,et al.  Clinical evaluation of proton radiotherapy for non-small-cell lung cancer. , 2003, International journal of radiation oncology, biology, physics.

[3]  Joao Seco,et al.  Effects of Hounsfield number conversion on CT based proton Monte Carlo dose calculations. , 2007, Medical physics.

[4]  David Pérol,et al.  A prospective study on radiation pneumonitis following conformal radiation therapy in non-small-cell lung cancer: clinical and dosimetric factors analysis. , 2004, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[5]  T. Hashimoto,et al.  Hypofractionated high-dose proton beam therapy for stage I non-small-cell lung cancer: preliminary results of a phase I/II clinical study. , 2007, International journal of radiation oncology, biology, physics.

[6]  Eike Rietzel,et al.  Four-dimensional proton treatment planning for lung tumors. , 2006, International journal of radiation oncology, biology, physics.

[7]  T. Kimura,et al.  CT appearance of radiation injury of the lung and clinical symptoms after stereotactic body radiation therapy (SBRT) for lung cancers: are patients with pulmonary emphysema also candidates for SBRT for lung cancers? , 2006, International journal of radiation oncology, biology, physics.

[8]  P. Brown,et al.  Proton beam radiotherapy versus three-dimensional conformal stereotactic body radiotherapy in primary peripheral, early-stage non-small-cell lung carcinoma: a comparative dosimetric analysis. , 2009, International journal of radiation oncology, biology, physics.

[9]  Luca Cozzi,et al.  On the dosimetric behaviour of photon dose calculation algorithms in the presence of simple geometric heterogeneities: comparison with Monte Carlo calculations , 2007, Physics in medicine and biology.

[10]  E. Yorke,et al.  Dosimetric advantage of using 6 MV over 15 MV photons in conformal therapy of lung cancer: Monte Carlo studies in patient geometries , 2002, Journal of applied clinical medical physics.

[11]  C B Begg,et al.  Racial differences in the treatment of early-stage lung cancer. , 1999, The New England journal of medicine.

[12]  T. Sakae,et al.  Comparisons of Dose-Volume Histograms for Proton-Beam versus 3-D Conformal X-Ray Therapy in Patients with Stage I Non-Small Cell Lung Cancer , 2009, Strahlentherapie und Onkologie.

[13]  K. Nihei,et al.  High-dose proton beam therapy for Stage I non-small-cell lung cancer. , 2006, International journal of radiation oncology, biology, physics.

[14]  R. Pötter,et al.  Can protons improve SBRT for lung lesions? Dosimetric considerations. , 2008, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[15]  Michael Flentje,et al.  Stereotactic Radiotherapy of Targets in the Lung and Liver , 2001, Strahlentherapie und Onkologie.

[16]  M Goitein,et al.  A pencil beam algorithm for proton dose calculations. , 1996, Physics in medicine and biology.

[17]  J. Wong,et al.  Computed tomography-guided frameless stereotactic radiotherapy for stage I non-small cell lung cancer: a 5-year experience. , 2001, International journal of radiation oncology, biology, physics.

[18]  N. Kanematsu,et al.  Scatter factors in proton therapy with a broad beam , 2006, Physics in medicine and biology.

[19]  P. Lambin,et al.  Particle therapy in lung cancer: where do we stand? , 2008, Cancer treatment reviews.

[20]  T. Araki,et al.  Stereotactic hypofractionated high‐dose irradiation for stage I nonsmall cell lung carcinoma , 2004, Cancer.

[21]  R K Ten Haken,et al.  Radiation pneumonitis as a function of mean lung dose: an analysis of pooled data of 540 patients. , 1998, International journal of radiation oncology, biology, physics.

[22]  R. Mcgarry,et al.  Stereotactic body radiotherapy for bilateral primary lung cancers: the Indiana University experience. , 2006, International journal of radiation oncology, biology, physics.

[23]  Zuofeng Li,et al.  Dose-volume comparison of proton therapy and intensity-modulated radiotherapy for prostate cancer. , 2008, International journal of radiation oncology, biology, physics.

[24]  Daniel W. Miller,et al.  Methodologies and tools for proton beam design for lung tumors. , 2001, International journal of radiation oncology, biology, physics.

[25]  Debra H Brinkmann,et al.  Incidence of radiation pneumonitis after thoracic irradiation: Dose-volume correlates. , 2007, International journal of radiation oncology, biology, physics.

[26]  Radhe Mohan,et al.  Significant reduction of normal tissue dose by proton radiotherapy compared with three-dimensional conformal or intensity-modulated radiation therapy in Stage I or Stage III non-small-cell lung cancer. , 2006, International journal of radiation oncology, biology, physics.

[27]  H. Yamashita,et al.  Extended collimator model for pencil-beam dose calculation in proton radiotherapy , 2006, Physics in medicine and biology.

[28]  Katia Parodi,et al.  Clinical implementation of full Monte Carlo dose calculation in proton beam therapy , 2008, Physics in medicine and biology.

[29]  Zhongxing Liao,et al.  Analysis of clinical and dosimetric factors associated with treatment-related pneumonitis (TRP) in patients with non-small-cell lung cancer (NSCLC) treated with concurrent chemotherapy and three-dimensional conformal radiotherapy (3D-CRT). , 2005, International journal of radiation oncology, biology, physics.

[30]  P. Kvale,et al.  Evaluation of the causes for racial disparity in surgical treatment of early stage lung cancer. , 2006, Chest.

[31]  Daniel W. Miller,et al.  Hypofractionated proton beam radiotherapy for stage I lung cancer. , 2004, Chest.

[32]  Masahiro Hiraoka,et al.  Clinical outcomes of a phase I/II study of 48 Gy of stereotactic body radiotherapy in 4 fractions for primary lung cancer using a stereotactic body frame. , 2005, International journal of radiation oncology, biology, physics.

[33]  K. Ohtomo,et al.  Exceptionally high incidence of symptomatic grade 2–5 radiation pneumonitis after stereotactic radiation therapy for lung tumors , 2007, Radiation oncology.

[34]  M. Goitein,et al.  Tolerance of normal tissue to therapeutic irradiation. , 1991, International journal of radiation oncology, biology, physics.

[35]  George Starkschall,et al.  Effects of interfractional motion and anatomic changes on proton therapy dose distribution in lung cancer. , 2008, International journal of radiation oncology, biology, physics.